Feline Infectious Peritonitis: A UK Perspective

Presentation Description / Summary: The treatment of feline infectious peritonitis (FIP) has developed over the last 5 years throughout Australia and the UK. Previously FIP had a fatality rate of 95%, however, the availability of nucleoside analogues has progressed the care of these patients exponentially. As the treatment is novel, protocols are constantly being updated to find the most affective and affordable methods for success. Within the UK, legal nucleoside analogues have been available since 2021. In this time a team of feline specialists have researched techniques for treatment and monitoring to ensure the best case outcomes for effected felines. As of June 1st 2024 the FDA has begun allowing prescriptions for GS441524 to be filled by US compounding pharmacies. It is vital that information regarding the use of these drugs is shared to maximise patient care. This presentation aims to highlight key literature findings regarding treatment of FIP. Secondly, it aims to share the experiences of FIP treatment within the UK veterinary community in the hope of assisting the onward progression of treatment in the USA. It is a fantastic opportunity for global collaboration in the veterinary field.